ARCH Venture Fund XIII, L.P. bought $12.5M of Lyell Immunopharma (LYEL)
Executed Mar 6, disclosed Mar 9, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 9), the stock returned -6.9% (delay-adjusted); from the execution session (Mar 6), +0.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
ARCH Venture Fund XIII, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Lyell Immunopharma, Inc. (LYEL). Across 1 priced purchase filing, the average 21-session return was +0.4% from execution and -6.9% from disclosure (delay-adjusted; derived). The largest single filing was $12.5M of LYEL (488,090 sh × $25.61, as filed), executed Mar 6.
Healthcare · Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for pat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→